PDCD1 and neoplasm: Due to its molecular and histological characteristics, such as lower immunogenicity, low TMB, fewer tumor-infiltrating lymphocytes, fewer dendritic cells, and lower levels of PD-1+ and CTLA4+ cells [15,32,33], the efficacy of ICI therapy has been limited, although promising data were also reported in R/M ACC [14,34].